NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION WOULD REQUIRE A PROSPECTUS, REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW, IS PROHIBITED OR WOULD OTHERWISE BE CONTRARY TO APPLICABLE RULES IN SUCH JURISDICTION, OR CANNOT BE MADE WITHOUT THE APPLICATION OF AN EXEMPTION FROM SUCH MEASURES. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

NANOLOGICA'S RIGHTS ISSUE REGISTERED, CONVERSION OF BTU INTO SHARES

Nanologica AB (publ) ("Nanologica" or the "Company") announces that the rights issue of units resolved by the Board of Directors on 23 October 2026, the outcome of which was announced on 19 November 2026 (the "Rights Issue"), has been registered with the Swedish Companies Registration Office. The last day of trading in paid subscribed units ("BTU") on Nasdaq Stockholm is Tuesday 1 December 2026. The record date with Euroclear Nordics AB for the conversion of BTU into shares is Friday 4 December 2026, and the new shares are expected to be available in the respective securities accounts and custody accounts on Tuesday 8 December 2026.

Conversion of BTU into shares
The Rights Issue was registered with the Swedish Companies Registration Office on 23 November 2026 (first partial registration) and 27 November 2026 (second partial registration), respectively. Through the Rights Issue, 50,989,401 units were issued, corresponding to 509,894,010 new shares, and the BTU allotted in the Rights Issue will now be converted into shares, whereby each BTU is converted into ten (10) shares. The last day of trading in BTU on Nasdaq Stockholm is Tuesday 1 December 2026. The record date with Euroclear Nordics AB is Friday 4 December 2026, and the new shares are expected to be available in the respective securities accounts and custody accounts on Tuesday 8 December 2026.
The conversion of BTU into shares takes place automatically and without any specific notification from Euroclear Nordics AB. Holders of nominee-registered holdings will be informed of the conversion in accordance with the procedures of their respective nominee.

Number of shares and share capital
Following the registration of the Rights Issue and the directed issue of 1,590,747 units, corresponding to 15,907,470 shares, to guarantors resolved by the Board of Directors on 21 November 2026, the number of shares in Nanologica amounts to 854,571,322 shares and the share capital to SEK 17,091,426.44.

Advisers
Nanologica has engaged Redeye AB, Bergs Securities AB and Navia Corporate Finance AB as Joint Bookrunners, and Advokatfirman Lindahl KB as legal adviser in connection with the Rights Issue. Bergs Securities AB is also acting as issuing agent in connection with the Rights Issue.

Important information

The publication, release or distribution of this press release may in certain jurisdictions be subject to restrictions by law, and persons in the jurisdictions in which this press release has been published or distributed should inform themselves about and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for any securities issued by the Company in any jurisdiction in which such offer or solicitation would be unlawful. In a member state of the European Economic Area ("EEA"), securities referred to in this press release may only be offered in accordance with applicable exemptions in the Prospectus Regulation.

This press release does not constitute an offer of, or an invitation to, acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration, or without the application of an exemption from registration, under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States absent registration, an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction in which such release, publication or distribution of this information would be contrary to applicable rules or where such action is subject to legal restrictions or would require additional registration or other measures than those required under Swedish law. Actions in violation of this instruction may constitute a violation of applicable securities legislation.

This press release is not a prospectus within the meaning of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. The Company has not authorised any offer to the public of securities in any member state of the EEA and no prospectus has been or will be prepared in connection with the Rights Issue. In each member state of the EEA, this press release is only directed at "qualified investors" in that member state as defined in the Prospectus Regulation.

This press release does not identify or purport to identify risks (direct or indirect) that may be associated with an investment in shares/units. An investment decision to acquire or subscribe for units in the Rights Issue may only be made on the basis of publicly available information.

Forward-looking statements

This press release contains forward-looking statements that relate to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the fact that they contain expressions such as "believes", "assesses", "expects", "anticipates", "intends", "estimates", "will", "may", "assumes", "should", "could" and, in each case, the negatives thereof, or similar expressions. Forward-looking statements should not be regarded as forecasts. The forward-looking statements in this press release are based on various assumptions, several of which are in turn based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialise or that they are correct. Because these assumptions

are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes may, for a variety of reasons, differ materially from those set out in the forward-looking statements. Such risks, uncertainties, contingencies and other material factors could cause actual events to differ materially from the expectations expressed or implied in this press release by the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct, and readers of this press release should not place undue reliance on the forward-looking statements herein. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or applicable stock exchange rules.

For further information, please contact

Johanna Westerberg
Director IR, Communications and Marketing
johanna.westerberg@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science group that offers advanced solutions for the development, manufacture and purification of pharmaceuticals. By combining expertise in materials science, nanotechnology and chemical process development with contract development and manufacturing services, Nanologica supports the value chain from early development to commercial production of pharmaceuticals. The Group has particular strength in complex molecules and peptide-based drugs. The Group has appx. 70 employees and is headquartered in Södertälje, Sweden. Nanologica's share (ticker: NICA) has been listed on Nasdaq Stockholm's main market since 2022. For more information, please visit www.nanologica.com.

Attachments

NANOLOGICA'S RIGHTS ISSUE REGISTERED, CONVERSION OF BTU INTO SHARES